Frequently Asked Questions
Clear answers when regulatory, clinical, or quality risk starts affecting the business.
These medical device FAQs answer the questions executive teams ask when approval timelines, evidence strategy, inspection readiness, or commercial confidence are under pressure.
Start with the topic closest to the decision in front of you. If the situation is more complex than a page can answer, request a confidential strategy discussion.
Request a Confidential Strategy Discussion
A private first conversation to assess the situation and determine whether SHOTUNE is the right fit.
General questions
How SHOTUNE engages and where founder-led advisory adds value.
These questions cover fit, engagement structure, executive accountability, and the situations that typically require senior judgment.
How is SHOTUNE different from large consulting firms or independent consultants?
SHOTUNE is founder-led, selectively scoped, and directly accountable. Clients receive integrated clinical, regulatory, and quality judgment under one senior leader rather than delegated consulting or generic deliverables.
What types of companies benefit most from working with SHOTUNE?
SHOTUNE is best suited to medical device companies operating in high-stakes regulatory environments, including startups approaching major milestones, growth-stage companies entering new markets, established manufacturers managing complex lifecycle demands, and organizations preparing for diligence, remediation, or regulator scrutiny.
We are a growth-stage company, not a large manufacturer. Are we the right fit?
Potentially, yes. Fit depends less on company size than on the materiality of the regulatory, clinical, or quality decision. SHOTUNE is often most valuable when a growth-stage company needs senior judgment before risk becomes expensive.
Do you work on project-based, fractional, or escalation support engagements?
Yes. Engagements are selectively scoped around the strategic need and may be structured as project-based support, fractional leadership, or escalation support during high-stakes approval, audit, diligence, or remediation periods.
How does SHOTUNE support diligence, transactions, or investor readiness?
SHOTUNE helps leadership identify and address regulatory, clinical, and quality exposures that may affect diligence outcomes, valuation confidence, or commercial narratives. The goal is clearer, more defensible executive readiness before scrutiny intensifies.
How do you integrate clinical evidence, regulatory strategy, and quality governance?
Under FDA and EU MDR, these functions are inseparable. SHOTUNE aligns evidence strategy, regulatory logic, quality system outputs, and risk management so approvals, inspections, and post-market obligations are supported by one coherent decision framework.
Regulatory strategy
Questions about submissions, pathways, regulator feedback, and escalation.
Use these answers when submission logic, market pathway, or regulator-facing strategy is no longer moving cleanly.
We have a stalled FDA or CE Mark submission. Can SHOTUNE step in midstream?
Yes. SHOTUNE is often engaged midstream when submissions stall because of evidence gaps, weak regulator-facing logic, or misalignment across clinical, regulatory, and quality functions. The work begins by identifying the root cause, clarifying the available options, and establishing the fastest defensible path forward.
Our pathway, classification, or predicate is still unclear. Can SHOTUNE help us decide?
Yes. Early ambiguity can delay development decisions, investor milestones, claims planning, evidence strategy, and portfolio sequencing. SHOTUNE helps leadership clarify the decision logic before downstream work becomes harder to unwind.
FDA or Notified Body feedback keeps escalating. How does SHOTUNE help?
Escalating feedback often signals a deeper misalignment between pathway, evidence, claims, and risk logic. SHOTUNE helps leadership reframe the strategy, strengthen the regulator-facing narrative, and reduce further review-cycle erosion.
Do you engage directly with FDA and Notified Bodies?
Yes. SHOTUNE supports pre-submission strategy, formal interactions, responses to questions, inspection readiness, and escalation planning. The focus is regulator-aligned communication and disciplined decision-making, not document throughput alone.
Can SHOTUNE help if prior advice has already led to rework or lost momentum?
Yes. SHOTUNE assesses what is still usable, identifies where the strategy broke down, and helps the team move forward with clearer decisions and stronger regulator alignment.
Our Notified Body is pushing back on technical documentation. Is that only a document problem?
Usually not. Pushback often reflects concern about evidence defensibility, benefit-risk logic, claims, or strategic coherence. SHOTUNE helps realign the underlying position so the documentation carries a stronger and more defensible story.
Clinical evidence
Questions about evidence strategy, claims support, CER, PMCF, and lifecycle obligations.
Use these answers when the data, claims, and regulator expectations are no longer lining up cleanly.
How does SHOTUNE design clinical strategy to meet FDA and EU MDR expectations?
SHOTUNE designs clinical strategy around regulator decisions, not data accumulation. The evidence plan is aligned to claims, benefit-risk, product maturity, and lifecycle obligations so the organization can avoid overbuilding, underbuilding, or pursuing work that does not support the decision.
Our existing data does not clearly support our claims. Can SHOTUNE help?
Yes. SHOTUNE helps determine whether the issue is a true evidence gap, a claims problem, or a broader strategy misalignment, then identifies the most defensible path forward.
Can you support clinical programs that are already underway or poorly aligned?
Yes. SHOTUNE reassesses what the existing data can credibly support, what needs to change, and how to move forward without unnecessary additional burden.
Our Notified Body is pushing back on our CER or PMCF. How do you handle this?
Pushback usually reflects concern with the underlying evidence logic, not only the wording. SHOTUNE helps realign CER, PMCF, claims, and benefit-risk rationale so the complete position is more coherent and defensible.
Do you support PMS and PMCF strategy?
Yes. SHOTUNE helps design proportionate post-market strategies that meet expectations, preserve resources, and support lifecycle decision-making across markets.
How do you integrate clinical evidence with quality and risk management?
SHOTUNE aligns evidence, claims, risk management, and post-market processes so the organization can defend one integrated position across clinical, regulatory, and quality functions.
Quality governance
Questions about QMS strength, inspections, CAPA, risk management, and recurring findings.
Use these answers when the system appears compliant but leadership still sees operational or regulator-facing exposure.
Our quality system passes audits, but regulators still raise concerns. Can SHOTUNE help?
Yes. Passing audits does not always mean the system is strategically strong. SHOTUNE evaluates whether outputs across quality, regulatory, and clinical functions are truly aligned under scrutiny and identifies where governance needs to be strengthened.
How does SHOTUNE build quality systems for scaling and global expansion?
SHOTUNE helps build quality systems that can absorb product growth, design changes, market expansion, and post-market obligations without repeated remediation.
Can SHOTUNE help us prepare for FDA inspections, Notified Body audits, or diligence review?
Yes. SHOTUNE helps identify weak points before they become findings, strengthen inspection readiness, and improve the cross-functional quality posture regulators, auditors, and investors actually evaluate.
How do you integrate risk management with clinical evidence and regulatory strategy?
Risk management should actively shape claims, evidence, PMS, and submission logic. SHOTUNE helps ensure risk files function as part of a connected decision system rather than standalone documentation.
Can SHOTUNE help when CAPAs, audit findings, or post-market issues keep recurring?
Yes. Recurring issues often point to a structural control problem rather than an isolated event. SHOTUNE helps leadership identify the deeper pattern, strengthen governance, and reduce repeated remediation.
What does SHOTUNE do differently from traditional quality consultants?
SHOTUNE approaches quality as enterprise control architecture, not only SOP maintenance. The work connects quality outputs to regulatory, clinical, risk, and executive decisions.
The next step
Need clarity on whether your situation requires escalation?
Bring the situation. The first conversation is used to understand the context, identify the decisions that matter, and determine whether SHOTUNE is the right fit.
Request a Confidential Strategy Discussion
One focused conversation. Clear ownership. No competing next step.